Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Ragon Institute of MGH, MIT and Harvard, Harvard Medical School, Cambridge, MA, USA.
Nat Commun. 2020 Oct 30;11(1):5493. doi: 10.1038/s41467-020-19057-5.
The relationship between SARS-CoV-2 viral load and risk of disease progression remains largely undefined in coronavirus disease 2019 (COVID-19). Here, we quantify SARS-CoV-2 viral load from participants with a diverse range of COVID-19 disease severity, including those requiring hospitalization, outpatients with mild disease, and individuals with resolved infection. We detected SARS-CoV-2 plasma RNA in 27% of hospitalized participants, and 13% of outpatients diagnosed with COVID-19. Amongst the participants hospitalized with COVID-19, we report that a higher prevalence of detectable SARS-CoV-2 plasma viral load is associated with worse respiratory disease severity, lower absolute lymphocyte counts, and increased markers of inflammation, including C-reactive protein and IL-6. SARS-CoV-2 viral loads, especially plasma viremia, are associated with increased risk of mortality. Our data show that SARS-CoV-2 viral loads may aid in the risk stratification of patients with COVID-19, and therefore its role in disease pathogenesis should be further explored.
SARS-CoV-2 病毒载量与 2019 年冠状病毒病(COVID-19)疾病进展风险之间的关系在很大程度上尚未明确。在这里,我们从患有各种严重程度 COVID-19 的参与者中定量检测了 SARS-CoV-2 病毒载量,包括需要住院治疗的患者、轻症门诊患者和已康复的感染者。我们在 27%的住院患者和 13%的 COVID-19 门诊患者中检测到了 SARS-CoV-2 血浆 RNA。在因 COVID-19 住院的患者中,我们报告说,可检测到的 SARS-CoV-2 血浆病毒载量越高,与更严重的呼吸道疾病严重程度、更低的绝对淋巴细胞计数以及更高的炎症标志物(包括 C 反应蛋白和 IL-6)相关。SARS-CoV-2 病毒载量,特别是血浆病毒血症,与死亡率增加相关。我们的数据表明,SARS-CoV-2 病毒载量可能有助于 COVID-19 患者的风险分层,因此其在疾病发病机制中的作用应进一步探讨。
Nat Commun. 2020-10-30
Ann Intern Med. 2020-11-17
J Infect Chemother. 2020-11
Med Mal Infect. 2020-6
Bull Exp Biol Med. 2025-8-28
Vaccines (Basel). 2025-7-28
Commun Med (Lond). 2025-7-1
JCI Insight. 2025-5-22
N Engl J Med. 2020-9-3
N Engl J Med. 2020-5-21
N Engl J Med. 2020-8-6
N Engl J Med. 2020-5-14
Lancet. 2020-5-2
Cell Host Microbe. 2020-4-21